IMI2 CARE Project: VRI-Inserm, coordinator of the European Public-Private Consortium, created to accelerate the development of Covid-19 treatments
The largest European initiative to accelerate the development of therapies for COVID-19 and future coronavirus threats was launched in Brussels on August 18. CARE (Corona Accelerated R&D in Europe) is a €77.7 million European public-private consortium of the Innovative Medicines Initiative (IMI) created to accelerate the development of therapies for Covid-19 and coronaviruses.
Professor Yves Lévy (Vaccine Research Institute, VRI; UMR 955, IMRB, INSERM / UPEC) is the Coordinator of this consortium which brings together 37 academic and industrial partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, Spain, Switzerland, the United Kingdom and the United States.
We congratulate him for this success, which we are proud of.
Read more : Press release of 18/08/2020
Etude de l’implication du gène NKX2‐1 dans les anomalies héréditaires de métabolisme du surfactant :
«Bénédicte Duriez - 12h – Webconférence»
Pending title :
«Oskar Karlsson - 12h – Webconférence ou amphi (sous-réserve)»
Date sub reserve and title pending :
«Peter Currie - 12h – Webconférence ou amphi 1 (en attente)»
All incoming seminars